Hematology Department

Universitair Ziekenhuis Leuven

Amyloidosis

Cardiomyopathies

Acoramidis

Eidos Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Universitair Ziekenhuis Leuven | Hematology Department

Site insights

Work at this site?

Active trials

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Trial sponsors